CLS Health, a prominent physician-owned healthcare medical group, is excited to announce the opening of its latest primary care facility, CLS Health Shadow Creek Primary Care Clinic, located at 10905 Memorial Hermann Dr., Ste. 130.
PEARLAND, Texas, December 14, 2023 (Newswire.com)
-
CLS Health continues its strategic expansion into the Greater Houston area. The Shadow Creek clinic is a vital component of CLS Health's comprehensive multi-specialty network within the Houston Southeast corridor and part of the medical group's strategic expansion into the Greater Houston area.
CLS Health Shadow Creek is projected to become a cornerstone of healthcare in Pearland, offering a spectrum of primary care services. It will provide exceptional health services to patients for years to come. The clinic is strategically positioned to address the diverse healthcare needs of the community.
Under the leadership of Dr. Tanvir Ahmed, a highly experienced and board-certified family medicine physician, CLS Health Shadow Creek is well-equipped to offer expert medical care. Dr. Ahmed’s expertise, combined with CLS Health's unique model, ensures a patient-centric approach that prioritizes individual well-being.
The Shadow Creek clinic can accommodate multiple providers, signaling CLS Health's commitment to expanding its reach and impact in the region. With a focus on holistic care, the clinic is designed to be a healthcare hub for the Pearland community.
CLS Health's expansion into Pearland marks another milestone in the organization's rapid growth trajectory. The introduction of new clinics and specialties reflects CLS Health's dedication to providing high-quality, personalized healthcare. The unique business model, centered around provider autonomy and ownership, remains a driving force in CLS Health's success.
"We are delighted to extend our footprint into Pearland, bringing our distinctive healthcare model to serve the community's needs. CLS Health Shadow Creek represents a continuation of our commitment to patient satisfaction and provider empowerment," remarked Megan Owen, CEO of CLS Health.
About CLS Health: CLS Health is a physician-owned healthcare group with a pioneering approach to comprehensive care. With over 33 locations and 160+ providers in the Greater Houston area, CLS Health emphasizes the satisfaction and empowerment of its physicians as a key element in delivering exceptional patient care. To learn more, visit cls.health.
Contact Information:
Isaiah Rincon
Media Relations Manager [email protected]
832-557-3338
NEW YORK, December 13, 2023 (Newswire.com)
-
AllergoSan USA is thrilled to announce that their Omni-Biotic AB 10 probiotic has been awarded the Practitioner’s Choice Award in the "Specialty and Herbal Supplements" category by Natural Practitioner Magazine. This esteemed recognition is particularly significant as it is based on product recommendations from practitioners, showcasing the trust and confidence they place in Omni-Biotic AB 10.
The Practitioner’s Choice Award, presented by Natural Practitioner Magazine, is a prestigious accolade honoring the most recommended products according to a nationwide survey of readers within the natural and alternative healthcare professional community. What sets this award apart is its basis in practitioner consensus, making it a true testament to the clinical impact of Omni-Biotic AB 10.
Hannah Kleinfeld, COO of AllergoSan USA, expressed her appreciation of the acknowledgment, stating, "We are honored to receive the Practitioner’s Choice Award for Omni-Biotic AB 10. This recognition reinforces our commitment to providing clinically-tested and highly effective products that make a real difference in gut health, wellness, and longevity. We are grateful for the support of our customers and healthcare practitioners."
Omni-Biotic AB 10 is a restorative probiotic designed to promote a balanced and diverse gut microbiome, the foundation of overall well-being. Clinically shown to reduce antibiotic-associated diarrhea, combat C. Diff infection, and inhibit other unwanted bacteria in the gut, Omni-Biotic AB 10 is frequently used in hospitals and nursing homes across Europe during and after antibiotic use, surgery, and chemotherapy.
Omni-Biotic, a top-selling European line introduced to the United States in 2019 by AllergoSan USA, offers targeted probiotic blends developed for stress, immunity, liver detox, gut restoration, and more. These high-performance probiotics are grounded in product-specific research and controlled clinical studies, ensuring a deep understanding of probiotic strain significance and synergistic performance for specific health outcomes.
About AllergoSan USA:
AllergoSan USA, a joint venture formed in 2019 with Austrian-based microbiome research institute Institut AllergoSan, is dedicated to bringing Omni-Biotic products to the U.S. The founding team recognized the need for deeply studied specialized probiotics in the U.S. AllergoSan USA aims to be the gold standard in probiotic supplements and gut health-promoting products, serving consumers, healthcare practitioners, pharmacies, and leading medical facilities. For more information visit www.omnibioticlife.com.
ASTCT logo The American Society for Transplantation and Cellular Therapy is an international professional membership association.
CHICAGO, December 13, 2023 (Newswire.com)
-
The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the US Food and Drug Administration’s (FDA) recently granted approval for two gene therapies aimed at treating Sickle Cell Disease (SCD). Casgevy, developed by Vertex Pharmaceuticals Inc., and Lyfgenia, developed by Bluebird Bio Inc., have been granted regulatory clearance for these therapies by the FDA after successful clinical trials and extensive review processes.
SCD is a genetically inherited red blood cell disorder. According to the Centers for Disease Control, SCD disproportionately affects Black or African American and Hispanic Americans in the United States. SCD affects an estimated 100,000 people in the United States, affecting one out of every 365 Black or African American births and one out of every 16,300 Hispanic American births.
ASTCT is a professional organization of health care professionals dedicated to the research, science and application of hematopoietic cell transplantation and related cellular therapies.
“Gene therapy offers a revolutionary approach to treating genetic diseases like sickle cell disease that have, in many cases, been deemed untreatable,” said Miguel-Angel Perales, MD, ASTCT President. “As is the case for many novel therapies, one of the challenges is ensuring that our patients have access to these potentially life-saving treatments. ASTCT strives to provide research and to address disparities in access to care and treatment for blood-related diseases and disorders.”
***
About ASTCT
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,700 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of hematopoietic cell transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field. Visit www.astct.org.
Contact Information:
Jennifer Kasowicz
ASTCT Marketing Director [email protected]
(312) 673-4970
Formulator Lindsey Duncan, CN, ND, notes this is not just another trendy coffee upgrade but a true coffee revolution in taste and health benefits.
SPRINGFIELD, Ohio, December 13, 2023 (Newswire.com)
-
All-In Nutritionals, LLC, creators of highly effective and potent natural supplements such as Ancient Energy, Jungle Greens, and Pure Collagen, announced today the addition of another exciting product with a unique, alkaline coffee formula called, “For the Love of Coffee.”
Each ingredient in the proprietary “For the Love of Coffee” formula was hand picked and includes generous amounts of six mushrooms grown on organic oats that provide amazing adaptogenic effects and organic black mission figs known to contain plenty of vitamins, minerals, and antioxidants. Also added are magnesium bicarbonate and potassium, which elevate the pH to create a non-acidic, alkaline coffee with a pH of 7.0 or above with each cup. The average cup of coffee has a pH between 4.0 and 5.0.
In addition, the formula contains organic MCT (Medium Train Triglycerides) oil, which creates a smooth, robust, and creamy flavor while providing healthy and beneficial “good fats.”
“This is far beyond your typical cup of morning joe,” said Lindsey Duncan, CEO of All-In Nutritionals. “Our coffee product is packed with so many nutrients and so many benefits that GIVE to your body instead of take away from your body.”
“Unfortunately, most coffee on the market is highly processed using harsh chemicals, may contain mold, can make you overly jittery and wired, and can be very acidic,” said Duncan. “For those who drink several cups a day, the average coffee can lead to an overly acidic body. Too much acid in the body can contribute to a list of health issues that are too long to list. With the launch of ‘For the Love of Coffee,’ customers will receive the opposite of what we call these ‘negative coffee effects.’”
The coffee beans are free from chemical processing, mold, and all the toxic chemicals. Duncan’s formula utilizes the cleanest, high-altitude, organic coffee beans rich in flavor, dark roasted, and freshly ground. The coffee is fair trade, organic and from local farmers in Guatemala and Honduras.
“We are extremely excited to be able to offer our customers this very unique and healthy product because everyone loves coffee,” said Duncan. “I mean, I love coffee. What I don’t love, though, is how acid, jittery, and nervous the average coffee makes my body. One might think with all these added ‘healthy ingredients,’ the flavor and consistency of the coffee would not be good. Nothing could be farther from the truth. The flavor is, in my opinion, one of the best things about this product. ‘For the Love of Coffee’ has been called ‘the best tasting coffee I’ve ever had’ by dozens and dozens of All-In Nutritionals customers.”
“If you want the perfect holiday gift, that’s not full of sugar, chemicals, acid, and little to no benefits, you can now give a loved one the gift of a healthy and incredible tasting coffee, for less than $1.50 a cup,” added Duncan. “In our eyes, this is a huge win for everyone. ‘For the Love of Coffee,’ and for that matter, any of our products, would make fantastic gifts this holiday season.”
About All-In Nutritionals Founded and created by Master Formulator, Herbalist, Doctor of Naturopathy, and Certified Nutritionist Lindsey Duncan, All-In Nutritionals is the leading provider of all-natural, pure, clinically studied and ingredient-tested supplements to aid people in nourishing, balancing, cleansing, and supporting the human body. All-In Nutritionals uses organic, wild-harvested, non-GMO ingredients grown and harvested in their natural state and masterfully formulated for both long-term and short-term success. All products are manufactured in All-In Nutritionals' pristine and FDA-registered manufacturing facility.
Contact Information:
Ellie Flores
Manager of Domestic & International Sales [email protected]
937-471-4801
With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a one-two punch to combat BRAF-mutated colorectal cancer and its “dismal prognosis.”
CHICAGO, December 13, 2023 (Newswire.com)
-
Many cancers caused by the mutation of the BRAF gene respond well to a class of immunotherapies known as BRAF-inhibitors. BRAF-mutated colorectal cancer, however, almost never does. Doctors have known this for years, but they are yet to find a treatment that works well for most patients.
“BRAF-inhibitors provide very different clinical outcomes,” said Dr. Scott Kopetz, a Professor and Associate Vice President for Translational Integration at The University of Texas MD Anderson Cancer Center. “They work amazingly well in melanoma, for example, but are less effective in colorectal cancer.”
“BRAF [in colorectal cancer] is that odd uncle who doesn’t behave like the rest of the family. The black sheep. Is he even related? The usual rules don’t apply.”
Dr. Kopetz and his team’s most recent studies of this black sheep are now moving from research in mice to clinical trials in humans. These trials were approved by the National Cancer Institute in October and will launch in early 2024.
The GI Research Foundation helped support the work with mice models, along with several other aspects of the team’s BRAF-related research. The $3.5 million grant is part of the foundation’s massive CA CURE initiative.
“Last year, we were able to deliver more than $18 million to researchers across the country to improve diagnostics and develop immunotherapies and personalized vaccines in gastrointestinal cancers through CA CURE,” said Katie Chudnovsky, chair of the GI Research Foundation’s Board of Directors. “Patients need treatments like those being developed by Dr. Kopetz – so very urgently – and we are thrilled to see this team’s work moving to clinical trials so quickly.”
BRAF-mutated colorectal cancer comes with a “dismal prognosis,” according to research in the International Journal of Molecular Sciences, and the median patient survives less than a year.
This new form of treatment for BRAF-mutated colorectal cancer relies on what Kopetz called a “two-hit hypothesis.” That is, these cancers are caused by the combination of mutations in the BRAF gene and epigenetic dysregulation. Epigenetic dysregulation refers to the fact that behaviors and environment can impact how a person’s genes behave.
Here, researchers have found that a mutation to the BRAF gene changes the production of proteins that cause healthy cells to grow into cancerous tumors. Other forms of BRAF-mutated cancer respond well to BRAF-inhibitor immunotherapy that can halt the production of those proteins.
In BRAF-mutated colorectal cancer, however, another piece of DNA is unable to express itself entirely. Those genes typically create natural tumor suppressors that fight early cancer growth. Carbon molecules called methyl groups attach themselves to the DNA and prevent the DNA from building cancer-suppressing proteins. That “methylation” is the epigenetic dysregulation in this case, likely caused by inflammation, diet, or external environmental factors.
If doctors can stop the proteins that cause cancer and stop the bromodomains, they might be able to produce a one-two punch to combat their double hit hypothesis. The treatment would slow BRAF-mutated colorectal cancer growth and encourage natural cancer suppressors.
That idea will be tested in the human trials that were recently approved by the National Cancer Institute. A BRAF-inhibitor, an EGFR-inhibitor, and a bromodomain-inhibitor will be administered to patients. This combined treatment was developed by Kopetz and his colleague Dr. Kunal Rai, an Associate Professor of Genomic Medicine at MD Anderson.
The research moved from the GI Research Foundation-funded mouse models to human trials exceptionally quickly, according to Kopetz.
“It’s rare for the pieces to come together like this,” he said. “Lots of times, this would be two years of work to get the human trials up and running. But we were able to show how clearly this approach worked in multiple mouse models and that really sped things up.”
Other funding from the GI Research Foundation will help speed things up even further. “The new technologies and techniques that Dr. Kopetz and his team are exploring will give them the ability to innovate that much faster. It provides the entire community with the means to gather high-quality data more quickly and get it into trials and ultimately into the clinic,” said Dr. David Rubin. Rubin is the Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at University of Chicago Medicine. He is also GI Research Foundation’s Senior Scientific Advisor.
“The GI Research Foundation has a legacy of funding high risk-high reward and innovative science, and doing so efficiently and extraordinarily effectively. Kopetz and his colleagues were recipients of a dedicated campaign that we launched in 2022 to tackle the most difficult challenges of colorectal cancer.”
“Support from the GI Research Foundation allows us to accelerate our work and try some out of the box stuff,” Kopetz said. “We have amazing animal models, but there’s no substitute for understanding cancer and treatments with the patients themselves. We want to develop the tools we need so we can learn as much as possible from them and help them as much and as quickly as we can.”
About the GI Research Foundation
The GI Research Foundation was founded in 1961 by grateful patients and friends of the late Dr. Joseph B. Kirsner, a pioneer in gastroenterology who devoted his life to medicine, teaching, and patient care. Today, the University of Chicago Medicine’s Digestive Diseases Center, which is supported by the foundation, is internationally recognized for research-driven medicine and its team of highly specialized physicians. For more information, see: https://giresearchfoundation.org/
About the University of Chicago Digestive Diseases Center
The Digestive Diseases Center at the University of Chicago Medicine is a collaborative, multidisciplinary network of physicians, researchers and affiliated health professionals who share a legacy of innovation and a common purpose: to improve the lives of patients who suffer from digestive diseases. For more information, see: https://www.uchicagomedicine.org/conditions-services/digestive-diseases
Contact Information:
Jackie Casey
Executive Director [email protected]
312-332-1350
SPARKS, Md., December 12, 2023 (Newswire.com)
-
TridentCare is pleased to announce the addition of Chris Tomlinson, MBA, CRA, FAHRA to the organization and its executive team. Chris recently assumed the role of Senior Vice President, Laboratory Operations and oversees the entire TridentCare Laboratory Network. His focus is on enhancing workflows, unifying TridentCare’s national lab network and growing both the primary customer segments (skilled nursing facilities) and commercial, governmental, and home-based lab programs. Chris says, “I am thrilled to join a company with the foresight to meet their customers ‘where they are’. This direction is where healthcare is evolving and as a lab and imaging leader, I can think of no better role for my background. I am excited to partner with a great group of leaders and further develop the next generation of healthcare services."
Chris has an extensive background in Radiology/Imaging & Clinical Lab/Pathology Services with over 20+ years of professional success. CEO Dan Buning indicates, "As a member of the Executive Leadership Team (ELT), Chris’s background in Radiology/Imaging is an added bonus; he will be able to lend his nationally recognized imaging expertise to TridentCare’s national portable imaging business where needed. Offering reliable, accurate, and timely lab service to both our core and new customer segments is a critical part of our company’s future.”
Prior to joining TridentCare, Chris was the Enterprise Vice President at Jefferson Health in Philadelphia where he oversaw the Clinical Lab/Pathology and Radiology/Imaging Services lines for eighteen (18) hospitals and clinics and became the first enterprise leader for the health system. As the Enterprise Vice President, Chris’s mandate was to organize, group, and consolidate service lines, standardizing lab and imaging across the different hospitals and partnership models. A huge undertaking with over 11M lab tests and more than 2M imaging studies per year.
Before his time with Jefferson Health, Chris spent fifteen (15) years at Children’s Hospital of Philadelphia where he led the radiology/imaging enterprise and launched a number of imaging joint ventures with other hospitals. Prior to that, Chris spent time at Arthur Andersen’s Business Consulting division where he focused on healthcare, and other offerings.
“Chris brings an enormous amount of insight and operational lab expertise that we know will complement and enhance our current infrastructure and national footprint,” says TridentCare COO Jeff Hooper. “Chris will help us accelerate our growth into non-traditional market segments for laboratory where we believe we are in a position to be one of the only national players in portable laboratory services.”
About TridentCare
Based in Sparks, Maryland, TridentCare is the leading provider of portable diagnostic services in the Country, operating in 38 states, servicing a wide variety of patients and clients. Each day, the company deploys experienced medical professionals and leading-edge technology to provide imaging, phlebotomy, laboratory, oxygen, and vascular services to tens of thousands of patients nationwide. For more information about TridentCare, please visit TridentCare.com, and follow us on LinkedIn, Facebook and Instagram.
Preventogen’s FDA-Cleared Microbicidal Liquid Polymer Ensures the Eradication of These Dangerous Pathogens on Contact While Forming a More Effective and Measurable Barrier to Optimize Healing
ST. LOUIS, December 12, 2023 (Newswire.com)
-
Many may not know the immense problem of antimicrobial resistance. A routine surgery or common cut can quickly become life-threatening due to an infection; an otherwise healthy person can quickly become fatally ill. These superbugs have already affected millions of Americans, and the problem of antimicrobial resistance is accelerating in our post-COVID world.
SEEKING A SOLUTION
In 2019, the Centers for Disease Control (CDC) in Atlanta published a 180-page compendium of the deadliest antibiotic-resistant threats: “Antibiotic resistance threats in the United States, 2019”. This groundbreaking work highlighted the 18 most dangerous pathogens and classified them as Urgent, Serious, or Concerning threats.
In its most recent publication, “COVID-19 Reverses Progress in Fight Against Antimicrobial Resistance in the U.S.”, the CDC cited a rise of 15% in hospitalization-related infections from 2019 to 2020. These pathogens are becoming stronger and more resistant on a global scale. In a January 2022 report, antimicrobial resistance was shown to be a leading cause of death globally, with the most significant burden in low-resource countries.
A SOLUTION WITH ROBUST KILLING PROPERTIES
Prevent-Plus has a solution in Preventogen™, a non-antibiotic approach to infection prevention. Since its inception in 2016, Prevent-Plus has performed in-vitro and flesh pad laboratory testing. After reading the 2019 CDC report, those most dangerous pathogens became vital targets.
Preventogen’s effectiveness has been definitively shown against every pathogen it has been tested against. All testing has been completed at Nelson Labs®, a Sotera Health company and an industry-leading, global provider of laboratory testing, performing over 900 rigorous microbiological and analytical laboratory tests.
“Our company is dedicated to the prevention of infection, which is why we continue to collect evidence to demonstrate Preventogen’s safety and efficacy in both lab and clinical settings,” said Brad Chartrand, CEO of Prevent-Plus.
Prevention is an FDA-cleared topical liquid polymer that kills bacteria, viruses, and fungi on contact. When applied to the skin, the patented polymer dries quickly. It creates a non-antibiotic, elastomeric barrier designed to protect wounds against water, germs, and dirt, providing clinicians with a more effective tool to fight against surgical-site infections and chronic wounds. Importantly, because the polymer is not a drug, there are no known organisms with tolerance or resistance to Preventogen.
CLINICAL PROOF OF SUCCESS
Preventogen’s safety and efficacy were demonstrated in a randomized, prospective trial in deformity correction with external fixators, one of the most infection-prone procedures in medicine, with the Preventogen patients showing 0 infections and the control arm with a 23% infection rate.
“With the use of Preventogen, we are seeing a dramatic decrease in bacterial colonization. We use this product as part of our infection prevention protocol in lower-extremity salvage and reconstruction in high-energy trauma and are also tracking its efficacy vs. superbugs. So far, we are very impressed,” commented Dr. Edgardo Rodriguez-Collazo, Director of the Postdoctoral Fellowship Complex Deformity Correction and Microsurgical Limb Reconstruction at Ascension Health.
“Preventogen lays down an impermeable barrier to bacteria, preventing biofilm formation. In our early clinical cases, we have found that chronic wounds thought not to be healable now go on to heal. We see demand for this product growing exponentially as the number of patients with chronic wounds grows annually; clinicians and payors are always looking for ways to heal more wounds in less time,” said Dr. Mary E. Hanley DO, FUHM, CWSP, FAPWCA, Medical Director Roper St. Francis Healthcare Wound Care, Hyperbaric Medicine and Limb Preservation Program.
About Preventogen™
Preventogen is a non-antibiotic, FDA-cleared microbicidal liquid agent that actively kills viruses, fungi, and bacteria on contact by lysing the cell membrane, leading to quick cell death. The liquid quickly dries, creating a transparent, biodegradable, odorless, and elastomeric film barrier. The flexible film barrier protects the wound from water, dirt, and oxygen. Carbon dioxide infused into Preventogen during manufacturing is released and lowers the wound bed's pH, which helps promote healing.
We are exploring additional strategic partnerships and market expansion based on robust scientific and clinical data.
About Prevent-Plus
Prevent-Plus, LLC provides innovative infection prevention polymer science used by professional healthcare providers and patients for wound care, infection prevention, and optimized healing across a wide range of clinical applications and specialties.
Preventogen Clinically Proven Efficacy
In a published clinical trial, the standard of care resulted in a 23% infection rate versus Preventogen at 0 infections.
Nicholas D. Gillitt, PhD, will assume the role of Chief Executive Officer of The Osmolality Lab, a global leader in osmolality testing and certifications.
KANNAPOLIS, N.C., December 12, 2023 (Newswire.com)
-
The Osmolality Lab announced today that Nicholas D. Gillitt, PhD, has been named as Chief Executive Officer. This announcement comes at a time of expansion and growth for the product testing business, which recently established an additional testing laboratory at the North Carolina Research Campus in Kannapolis earlier this year.
Nicholas D. Gillitt, PhD, is a seasoned scientific executive with broad management experience encompassing collaborative research, analytical service provision, and sales/marketing efforts. His experience in human nutrition will be invaluable in understanding how hydration affects us metabolically. One of his key attributes that will be leveraged by The Osmolality Lab in this new role is managing a company's ability to market effectively from a sound, scientific platform.
For over 30 years, Nick has contributed to pushing back the frontiers of science, co-authoring over 60 papers in peer-reviewed scientific journals in the process. Most recently, this effort focused on the field of human nutrition during employment with industry leaders. His experience included serving as Vice President of Nutrition Research for Dole Food Company and managing the Dole Nutrition Institute's research and consumer education efforts. Nick's considerable experience in the application of the nutrition sciences, at both clinical and laboratory bench levels, to the field of customer education will aid The Osmolality Lab's efforts in educating consumers of the importance of osmolality in the hydration products they buy.
"Osmolality is important as it tells us how well a hydration product will work. If you are experiencing dehydration, no matter whether you are a world-class athlete chasing down a record or a kid playing AYSO soccer on a hot day at the weekend, having a 'best in class' hydration option at hand matters," Nick says. "Consumers should be able to make an informed choice at the shelf when considering a hydration product; osmolality certifications allow for this. It's good for the industry and even better for the consumer."
The Osmolality Lab, the global leader in osmolality product testing, was founded in 2018 with the mission “to improve health and safety for all consumers by providing unique services to partners driven to create excellence in their category”. Their team tests and certifies in a variety of industries such as hydration beverages, functional beverages, spring waters, and personal lubricants, skin care, and more to help clients and consumers learn more about how the product performs so they can purchase with confidence. Products that meet The Osmolality Lab's strict testing and evaluation criteria can also be awarded THE OSMOLab CERTIFIEDSM mark to help communicate the commitment to transparency and product quality to consumers.
Arrow Benefits Group Celebrates Community Accolade Encouraging Diversity
PETALUMA, Calif., December 12, 2023 (Newswire.com)
-
Arrow Benefits Group Senior Benefits Advisor Rosario Avila has been honored with the North Bay Business Journal’s Diversity in Business Award. Avila is recognized as an outstanding diverse leader, working to empower the community in the North Bay. The award celebrates individuals whose contributions build community and a positive work environment where all people are represented and supported.
Avila has been involved in several local organizations such as Sonoma Family Meal, Hispanic Chamber of Commerce, LatinX Hub, and Los Cien. In her role as the leader of Arrow’s Spanish Language Division — Alianza — Avila brings her passion for community to the workplace. “I’m very humbled by this award,” says Avila. “As the youngest child of immigrants, I saw firsthand how thoughtful communication among different people helps to limit misunderstandings. I’m so proud that Arrow understands this and works to ensure our clients receive culturally sensitive information.” To learn about Avila and Arrow’s diversity work, please visit https://www.arrowbenefitsgroup.com/spanish-language-division/ or call 707-799-9274.
Translating for a population and its language is more than just converting information; it takes a deeper understanding, re-interpretation, and communication of words and ideas. Avila understands this concept exceptionally well. She helped Arrow build its Spanish Division, Alianza, to do exactly that, allowing an entire diverse community to make the best use of its benefits and reduce financial losses for its clients — the program had been a win-win for employees and employers alike.
Avila’s efforts to ensure equitable access to information have been recognized in the past. She has been nationally recognized as an Employee Benefits Advisor of the Year and received an Excellence in Advising Award. Avila was honored with the North Bay Business Journal Latino Business Leadership award in 2018.
“One of Arrow’s goals is to build a diverse, equitable, and inclusive environment where our employees can grow, thrive, and be supported,” says Joe Genovese, Arrow’s CEO and Managing Principal. “This award is a great achievement for Rosario and the Arrow team at large.”
About Arrow Benefits
For more than 30 years, Arrow has been a true partner to employers by delivering employee benefits expertise, service excellence, and strategic consulting designed to meet the unique needs of its clients. In 2019, Arrow Benefits Group co-founded Patriot Growth Insurance Services (PGIS), which is now one of the largest benefits consulting and brokerage networks in the country. Patriot and Arrow are aligned with TRUE Network of Advisors, a national collaboration of independent agencies and brokerages. Learn more at https://www.arrowbenefitsgroup.com/ or call 707-992-3780.
Exclusive partnership provides a complete, end-to-end value-based care delivery, payment model and advanced analytics solution for payers, providers, payviders and large employers to improve quality, cost control, health equity, patient/member satisfaction, and more
MedeAnalytics logo
RICHARDSON, Texas, December 12, 2023 (Newswire.com)
-
MedeAnalytics, a healthcare analytics software-as-a-service (SaaS) leader enabling clinical, financial and operational analytics for healthcare providers, payers, payviders, employers, and other key stakeholders in the ecosystem, announced today an exclusive strategic partnership with HSBlox, a leading technology platform for value-based care contract management and administration that operationalizes complex contracts, enables transparency, and simplifies communication between stakeholders. This partnership combines best-in-class, outcomes-based analytics with contract and financial administration into one powerful platform, providing an end-to-end value-based care solution purpose-built to meet all needs of healthcare organizations in successfully moving to more value-based care programs and whole-person healthcare. When coupled with the MedeAnalytics Managed ActionTM ecosystem and strategic consulting services, the combined platforms and partnership will represent the industry’s most complete value-based care management solution.
The Health Care Payment & Learning Action Network survey of health plan executives showed two-sided risk contracts expanded 24.5% over the previous year. Transitioning from fee-for-service to Alternative Payment Models (APMs), especially risk-based APMs, is a daunting challenge for both providers and payers as it can be difficult to operationalize and scale across multiple contracts and payment models. Data sharing continues to be a pain point. Being able to share timely data with proactive and actionable insights is an imperative for accountable care with failure often leading to fines, penalties, and an inability to achieve reimbursement targets.
"As healthcare organizations expand the number of value-based care contracts and alternative payment models they support, they need a scalable solution that’s low-lift and provides actionable insights," said Rahul Sharma, CEO of HSBlox. "That's why this partnership is powerful. The MedeAnalytics customer base represents the broadest reach of value-based care stakeholders in the industry supporting providers, managed care organizations, commercial payers and brokers, and this combined solution will provide a level of support unmatched in the industry. The scalability and flexibility of our platform combined with MedeAnalytics can support all the nuanced needs associated with successful programs."
By seamlessly integrating into the MedeAnalytics end-to-end platform, providers, health plans and employers can engage in a single solution and extend into payment modeling and facilitation. This means customers will be uniquely enabled to surface insights, prioritize action, and measure impact in the most efficient environment available in the industry. As one example, organizations can leverage historical utilization patterns and performance to identify and model different types of value-based care programs and payment models. With this increased visibility and data integration, MedeAnalytics can deliver insights and recommendations that are suitable for a particular program, model out the contract terms, and operationalize that contract to improve the quality of care and performance while keeping costs down and complying with regulations.
"Value-based care represents a better future for healthcare, but without smart solutions using cutting-edge innovation like our data fabric, augmented analytics, and best-in-industry data interoperability, organizations will continue to struggle with the multiple, often disconnected platforms and blending, prepping and normalizing data between systems," said Steve Grieco, CEO of MedeAnalytics. "By integrating the HSBlox platform into our ecosystem, organizations will not only gain complete visibility into their APM performance, but also, they will have our industry-leading Managed Action ecosystem infrastructure to ensure all activities supporting value-based care transformation are coordinated and aligned with the most important outcomes. This advancement will maximize value-based care performance and provide better patient outcomes at a lower cost of care delivery."
If you’d like to learn more about this exclusive partnership and how it can propel and scale healthcare organizations into value-based care, please reach out. We also offer strategic consulting services through MedeConsulting. Schedule a complimentary discovery call with our experts to uncover potential impact.
###
About HSBlox
HSBlox empowers healthcare organizations with the tools and support to manage value-based programs successfully and sustainably. Our platform provides end-to-end administration, simplifies communication between stakeholders, and operationalizes complex contracts for the full range of reimbursement models. Wherever you are on your value-based journey, we’ll meet you there with smart, secure, scalable solutions. To learn more, browse our website and visit our LinkedIn page.
About MedeAnalytics® With over 30 years in the industry, MedeAnalytics is a leader in healthcare analytics. Using a data fabric-enabled cloud platform, our SaaS solutions run on cutting-edge innovation and enable measurable impact for healthcare payers, providers and payviders. With the most advanced data orchestration and interoperability in healthcare, organizations count on us to deliver actionable insights that improve financial, operational and clinical outcomes. To date, we’ve helped uncover millions of dollars in savings annually. To learn more, browse our website, LinkedIn and featured insights.
Media Contacts:
HSBlox Philip Anast Amendola Communications 312.576.6990 [email protected]
MedeAnalytics Caryn Tomer AVP, Marketing for MedeAnalytics 618.579.9717 [email protected]
